Nanobiotix S.A. Logo

Nanobiotix S.A.

Developing a nanotherapeutic radioenhancer that amplifies radiation to destroy solid tumors.

NBTX | NDAQ

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
60 RUE DE WATTIGNIES, 75012 PARIS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Nanobiotix S.A. is a late-stage clinical biotechnology company pioneering the discovery, development, and commercialization of physics-based nanotherapeutics. The company's lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed for direct injection into solid tumors. When activated by radiotherapy, NBTXR3 locally amplifies the radiation dose within the tumor, aiming to enhance cancer cell destruction without increasing exposure to surrounding healthy tissues. This process is also intended to prime the immune system to attack metastatic cancer cells. Through a global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson Company, Nanobiotix is co-developing NBTXR3, initially focusing on cancers of the head, neck, and lungs for patient populations with limited treatment options.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Nanobiotix S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Nanobiotix S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Nanobiotix S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Alpha Cognition Inc. Logo
Develops and commercializes novel treatments for neurodegenerative diseases like Alzheimer's and ALS.
United States of America ACOG
Alteogen Inc. Logo
Biotech firm developing next-gen ADCs and biobetters with proprietary platform technologies.
South Korea 196170
ALTERITY THERAPEUTICS LTD Logo
Developing therapies for Parkinsonian disorders and MSA by inhibiting protein aggregation.
United States of America ATHE
Alto Neuroscience, Inc. Logo
Developing precision medicines for depression and schizophrenia using a brain biomarker platform.
United States of America ANRO
ALUMIS INC. Logo
Develops targeted oral therapies for immune-mediated diseases using precision immunology.
United States of America ALMS
Alvotech Logo
Develops and manufactures affordable biosimilar medicines for patients worldwide.
United States of America ALVO
Alvotech Holdings S.A Logo
Develops and manufactures affordable biosimilar medicines for global patient access.
Luxembourg ALVO
ALX ONCOLOGY HOLDINGS INC Logo
Clinical-stage firm developing CD47 inhibitors for hematologic and solid tumors.
United States of America ALXO
Alzamend Neuro, Inc. Logo
Developing lithium & vaccine therapies for neurodegenerative & psychiatric disorders.
United States of America ALZN
Alzinova AB Logo
Developing targeted immunotherapies, including a vaccine, for Alzheimer's disease.
Sweden ALZ

Talk to a Data Expert

Have a question? We'll get back to you promptly.